Little House Capital LLC Has $2.07 Million Stock Holdings in Amgen Inc. (NASDAQ:AMGN)

Little House Capital LLC boosted its holdings in shares of Amgen Inc. (NASDAQ:AMGN) by 8.7% in the fourth quarter, according to its most recent filing with the SEC. The firm owned 7,190 shares of the medical research company’s stock after acquiring an additional 573 shares during the period. Little House Capital LLC’s holdings in Amgen were worth $2,071,000 as of its most recent filing with the SEC.

Other institutional investors have also recently bought and sold shares of the company. Walkner Condon Financial Advisors LLC lifted its position in Amgen by 42.2% in the 3rd quarter. Walkner Condon Financial Advisors LLC now owns 1,330 shares of the medical research company’s stock valued at $357,000 after acquiring an additional 395 shares in the last quarter. Lantz Financial LLC lifted its position in Amgen by 4.8% in the 3rd quarter. Lantz Financial LLC now owns 2,115 shares of the medical research company’s stock valued at $568,000 after acquiring an additional 96 shares in the last quarter. Covenant Partners LLC bought a new stake in Amgen during the 3rd quarter worth about $690,000. Linden Thomas Advisory Services LLC lifted its position in Amgen by 1.5% during the 3rd quarter. Linden Thomas Advisory Services LLC now owns 6,861 shares of the medical research company’s stock worth $1,844,000 after buying an additional 100 shares in the last quarter. Finally, Golden State Equity Partners lifted its position in Amgen by 1.4% during the 3rd quarter. Golden State Equity Partners now owns 8,658 shares of the medical research company’s stock worth $2,327,000 after buying an additional 120 shares in the last quarter. Institutional investors and hedge funds own 76.50% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts have recently weighed in on the stock. Leerink Partnrs lowered shares of Amgen from an “outperform” rating to a “market perform” rating in a research note on Wednesday, February 7th. Raymond James assumed coverage on shares of Amgen in a research note on Thursday, March 28th. They set a “market perform” rating on the stock. Oppenheimer restated an “outperform” rating and set a $350.00 price objective on shares of Amgen in a research note on Thursday, February 1st. Morgan Stanley lowered their price objective on shares of Amgen from $281.00 to $278.00 and set an “equal weight” rating on the stock in a research note on Wednesday, February 7th. Finally, TD Cowen lowered their price objective on shares of Amgen from $370.00 to $360.00 and set a “buy” rating on the stock in a research note on Wednesday, April 17th. Ten investment analysts have rated the stock with a hold rating and ten have issued a buy rating to the company’s stock. According to MarketBeat, Amgen presently has a consensus rating of “Moderate Buy” and a consensus target price of $296.95.

Amgen Stock Up 0.2 %

NASDAQ:AMGN traded up $0.60 during trading hours on Friday, reaching $269.98. The company had a trading volume of 2,436,959 shares, compared to its average volume of 2,035,139. Amgen Inc. has a twelve month low of $211.71 and a twelve month high of $329.72. The firm has a market cap of $144.81 billion, a price-to-earnings ratio of 21.62, a P/E/G ratio of 2.61 and a beta of 0.58. The business’s 50-day simple moving average is $275.10 and its two-hundred day simple moving average is $281.52. The company has a quick ratio of 1.13, a current ratio of 1.65 and a debt-to-equity ratio of 10.14.

Amgen (NASDAQ:AMGN) last issued its quarterly earnings data on Tuesday, February 6th. The medical research company reported $4.71 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $4.66 by $0.05. The company had revenue of $8.20 billion for the quarter, compared to the consensus estimate of $8.13 billion. Amgen had a return on equity of 154.27% and a net margin of 23.83%. The firm’s revenue was up 19.8% compared to the same quarter last year. During the same quarter last year, the business posted $4.09 earnings per share. On average, equities analysts expect that Amgen Inc. will post 19.43 earnings per share for the current year.

Amgen Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, June 7th. Stockholders of record on Friday, May 17th will be paid a dividend of $2.25 per share. The ex-dividend date is Thursday, May 16th. This represents a $9.00 dividend on an annualized basis and a dividend yield of 3.33%. Amgen’s dividend payout ratio (DPR) is currently 72.06%.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.